Tet2 Regulates Osteoclast Differentiation by Interacting with Runx1 and Maintaining Genomic 5-Hydroxymethylcytosine (5hmC).
- Author:
Yajing CHU
1
;
Zhigang ZHAO
2
;
David Wayne SANT
3
;
Ganqian ZHU
4
;
Sarah M GREENBLATT
5
;
Lin LIU
6
;
Jinhuan WANG
7
;
Zeng CAO
6
;
Jeanette Cheng THO
4
;
Shi CHEN
4
;
Xiaochen LIU
4
;
Peng ZHANG
4
;
Jaroslaw P MACIEJEWSKI
8
;
Stephen NIMER
5
;
Gaofeng WANG
3
;
Weiping YUAN
1
;
Feng-Chun YANG
9
;
Mingjiang XU
10
Author Information
- Publication Type:Journal Article
- Keywords: 5hmC; Macrophage; Osteoclast; Runx1; Tet2
- MeSH: 5-Methylcytosine; analogs & derivatives; chemistry; metabolism; Animals; Cell Differentiation; Cells, Cultured; Core Binding Factor Alpha 2 Subunit; genetics; metabolism; DNA-Binding Proteins; physiology; Genome; Genomics; Mice; Mice, Knockout; Osteoclasts; cytology; metabolism; Proto-Oncogene Proteins; physiology
- From: Genomics, Proteomics & Bioinformatics 2018;16(3):172-186
- CountryChina
- Language:English
- Abstract: As a dioxygenase, Ten-Eleven Translocation 2 (TET2) catalyzes subsequent steps of 5-methylcytosine (5mC) oxidation. TET2 plays a critical role in the self-renewal, proliferation, and differentiation of hematopoietic stem cells, but its impact on mature hematopoietic cells is not well-characterized. Here we show that Tet2 plays an essential role in osteoclastogenesis. Deletion of Tet2 impairs the differentiation of osteoclast precursor cells (macrophages) and their maturation into bone-resorbing osteoclasts in vitro. Furthermore, Tet2 mice exhibit mild osteopetrosis, accompanied by decreased number of osteoclasts in vivo. Tet2 loss in macrophages results in the altered expression of a set of genes implicated in osteoclast differentiation, such as Cebpa, Mafb, and Nfkbiz. Tet2 deletion also leads to a genome-wide alteration in the level of 5-hydroxymethylcytosine (5hmC) and altered expression of a specific subset of macrophage genes associated with osteoclast differentiation. Furthermore, Tet2 interacts with Runx1 and negatively modulates its transcriptional activity. Our studies demonstrate a novel molecular mechanism controlling osteoclast differentiation and function by Tet2, that is, through interactions with Runx1 and the maintenance of genomic 5hmC. Targeting Tet2 and its pathway could be a potential therapeutic strategy for the prevention and treatment of abnormal bone mass caused by the deregulation of osteoclast activities.
